Executive Team

We are a team of seasoned biotechnology professionals with significant experience developing and lauching leading pharmaceutical products.

Rob Etherington

CEO/President

Rob Etherington is the President/CEO of Clene Nanomedicine, Inc., a Phase 2 clinical-stage biopharmaceutical pursuing drug therapies for Multiple Sclerosis, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease).

Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position over the drug Lipitor. He left Pfizer in 2000 to be the founding Director of Marketing during the IPO year of Swiss-based, Actelion Pharmaceuticals, focused in cardiopulmonary disease. Actelion was the largest biopharmaceutical company based in the EU until Johnson & Johnson Pharmaceuticals purchased Actelion. Etherington was the first US commercial employee, leading U.S. commercial operations and serving as Chair of the US Commercial Strategic Team, with responsibility for five marketed drugs. As CEO of Clene Nanomedicine, Etherington has raised ~$70M to-date to fund Clene’s drug development efforts. Clene’s first drug, CNM-Au8, is presently in its first Phase 2 clinical human trial, VISIONARY-MS, a clinical study of remyelination in multiple sclerosis patients, and will commence REPAIR-PD and REPAIR-ALS by 2019 in neurodegeneration. A pipeline of other therapeutic nanotherapeutics are presently in preclinical development.

Mark Mortenson

Chief Science Officer

Mark Mortenson is the Co-Founder and Chief Science Officer of Clene. Mortenson is the co-inventor of the technology platform developed to produce Clean-Surface Nanocrystal (CSN™) therapeutics, as well as the inventor/co-inventor on 17 other US patents and hundreds of corresponding foreign patents.

Mark is a former chief patent counsel responsible for approximately 5500 patents and patent applications in the United States and 44 foreign countries, and is the former chief operating officer of research, development, and manufacturing for an advanced materials-based company of over 300 employees. Mark holds a BS in physics and a BS in ceramic engineering from Alfred University, an MS in material science from Pennsylvania State University, and a JD from George Washington University.

Robert Glanzman MD, FAAN

Chief Medical Officer

Dr. Glanzman is board certified in neurology,
and a Fellow of the American Academy of Neurology.

Robert received his doctorate in medicine from Wake Forest University, completed a residency in neurology at the University of Michigan, and completed fellowship training in diagnostic nuclear medicine at Duke University. Robert spent 7 years as Assistant Clinical Professor at Michigan State University, where he had a busy clinical practice, taught residents and acted as principal investigator for numerous clinical trials. Robert joined industry in 1999. He spent eight years at Pfizer as Senior Medical Director and Team Leader of the medical affairs team for interferon beta-1a (Rebif). In 2007, he moved to Novartis where he oversaw the successful Phase III development of fingolimod (Gilenya) and the commercial launch of interferon beta-1b (Extavia), in the US. In 2009, he was recruited by the Roche Group as Global Development Team Leader for the ocrelizumab (Ocrevus) program from the end of Phase II through the initiation of Phase III, in 2012. Following this, he held positions of increasing responsibilities at Purdue Pharmaceuticals, Nektar Therapeutics and, from December 2015 to June 2019, was Chief Medical Officer of GeNeuro S.A.. Robert has co-authored numerous peer-reviewed publications.

Michael Hotchkin

Chief Business Officer

Michael Hotchkin is the Chief Business Officer of Clene. He has over twenty years of experience in pharmaceutical commercialization, planning, strategy development, and medical affairs.

He started his career at Parke-Davis pharmaceuticals and was part of the founding team at Actelion US, Inc. launching multiple best-in-class products for orphan disorders. Prior to joining Clene Nanomedicine Inc., Hotchkin led the commercialization efforts for Actelion’s Genetics Business Unit including clinical development activities, which resulted in the doubling of sales for two different pharmaceutical drugs. During his 12-year tenure at Actelion he implemented new market planning activities for Actelion globally, directed U.S. strategy development, and led marketing activities for both multiple medicines. At Clene, he leads commercial planning and strategy development, preclinical translational medicine, and health regulatory authority filings.

Matt Gardner J.D., CPA

Chief Financial Officer

Matt Gardner is the VP Finance, Acting Chief Financial Officer for
Clene Nanomedicine, Inc. He has over 20 years of experience in finance and accounting, including an extensive background in tax credits.

Matt is a certified public accountant and licensed attorney, attending the University of Utah for his accounting degree and Brigham Young University for law school. Matt has broad experience with technology companies through his work at KPMG and Ernst & Young. From 2006 to 2012, he was the Tax Director of UPS Freight, a North American division of UPS, the multi-billion dollar Fortune 100 global logistics company. He also worked for Blu., a Chinese energy sector start-up company, prior to joining Clene Nanomedicine. As VP Finance, Acting Chief Financial Officer, Matt has organized over $1M dollars in tax credits to improve Clene’s cash flows. He also serves as a Director of Clene Australia Pty Ltd.